The effect of 0.05% Cyclosporine A eyedrops in patients after cataract surgery

ISRCTN ISRCTN10173448
DOI https://doi.org/10.1186/ISRCTN10173448
Submission date
28/03/2020
Registration date
06/04/2020
Last edited
12/01/2021
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Eye Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Cataracts are when the lens of your eye, a small transparent disc, develops cloudy patches. Cataract surgery involves replacing the cloudy lens inside the eye with an artificial one.
The Meibomian glands along the rims of the eyelid produce meibum, an oily substance that prevents evaporation of the eye's tear film. Meibomian gland dysfunction (MGD) often occurs after cataract surgery.
Cyclosporine A (CsA) eye drops are a new treatment for MGD and dry eye syndrome after cataract surgery. The usual treatment is with Carboxymethyl cellulose (CMC) eye drops.

Who can participate?
Adult cataract patients with normal lid position and closure and not suffering from any ocular diseases.

What does the study involve?
Participants will be randomly allocated to receive 0.05% CsA or 0.5% Carboxymethyl cellulose (CMC) over three months following cataract surgery. Subjective and objective assessments are performed in each preoperative and postoperative visit.

What are the possible benefits and risks of participating?
When participating in the study, there might be no risks or benefits for patients. This is a controlled study comparing the group with and without the use of specific eye drops that are commercially available and have clinical safety. There is no direct benefit when the patient participates in the study.

Where is the study run from?
Department of Ophthalmology, Pusan National University School of Medicine, Yangsan (South Korea)

When is the study starting and how long is it expected to run for?
April 2019 to November 2019

Who is funding the study?
Pusan National University Yangsan Hospital (South Korea)

Who is the main contact?
Dr Min Seung Min Seung, kangminseung91@gmail.com

Contact information

Dr Min Seung Kang
Scientific

Pusan National University School of Medicine
20-Geumo-ro
Mulgeum-eup
Yangsan
50612
Korea, South

ORCiD logoORCID ID 0000-0001-5026-4117
Phone +82 55-360-1447
Email kangminseung91@gmail.com

Study information

Study designProspective randomized double-masked comparative clinical trial
Primary study designInterventional
Secondary study designRandomised parallel trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleEfficacy of 0.05% Cyclosporine A on the lipid layer and meibomian gland after cataract surgery: a randomized, double-masked study
Study objectives0.05% cyclospoine A might improve MGD dysfunction and dry eye syndrome by comparison to 0.5% carboxymethyl cellulose after cataract surgery.
Ethics approval(s)Approved 04/04/2019, Pusan National University Yangsan Hospital Institutional Review Board (#20 Geumo-ro, Mulgeum-eup, Yangsan 50612, South Korea; +82-55-360-3854; pnuyhirb@gmail.com), ref: 05-2019-049
Health condition(s) or problem(s) studiedDry eye syndrome, meibomian gland dysfunction
InterventionEligible patients are randomized using the random number method into two treatment groups. The first group will use 0.05% CsA ophthalmic emulsion (Restasis®, Allergan Inc., Irvine, CA) twice daily over three months following cataract surgery. The second group receive standard postoperative treatment with 0.5% carboxymethyl cellulose (CMC) (Refresh plus®, Allergan Inc., Irvine, CA).
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)0.05% CsA ophthalmic emulsion (Restasis®, Allergan Inc., Irvine, CA); 0.5% carboxymethyl cellulose (CMC) (Refresh plus®, Allergan Inc., Irvine, CA)
Primary outcome measureAt baseline and three months.
1. Ocular surface status parameters:
1.1. Lipid layer thickness (LLT) using an interferometer
1.2. Schirmer’s type I test
1.3. Tear breakup time (TBUT)
2. Ocular Surface Disease Index (OSDI) questionnaire to evaluate the patients’ symptoms
3. Meiboscores with the LipiView® interferometer to calculate the degree of meibomian gland dysfunction
Secondary outcome measuresnone
Overall study start date01/01/2018
Completion date30/11/2019

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants50 patients
Total final enrolment50
Key inclusion criteriaAdult cataract patients with normal lid position and closure and not suffering from any ocular diseases
Key exclusion criteria1. Patients who had used topical anti-inflammatory, antibiotic, or other medication during the previous 90 days before surgery
2. Eyes with a history of trauma, ocular surgery, laser or systemic treatment known to affect tear secretion, autoimmune disease, current use of contact lenses, and/or history of slit-lamp evidence of eye surface disorders
Date of first enrolment04/04/2019
Date of final enrolment31/05/2019

Locations

Countries of recruitment

  • Korea, South

Study participating centre

Pusan National University School of Medicine
Department of Ophthalmology
20-Geumo-ro
Mulgeum-eup
Yang San
50612
Korea, South

Sponsor information

Pusan National University Yangsan Hospital
Hospital/treatment centre

20-Geumo-ro
Mulgeum-eup
Yangsan
50612
Korea, South

Phone +82 55-360-1447
Email jiel75@hanmail.net
Website http://www.pnuyh.or.kr/pnuh/main/main.do?rbsIdx=1
ROR logo "ROR" https://ror.org/04kgg1090

Funders

Funder type

Hospital/treatment centre

Pusan National University Yangsan Hospital

No information available

Results and Publications

Intention to publish date20/04/2020
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryData sharing statement to be made available at a later date
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal.
IPD sharing planThe current data sharing plans for this study are unknown and will be available at a later date

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol file 15/05/2020 No No
Results article results 11/01/2021 12/01/2021 Yes No

Additional files

ISRCTN10173448_PROTOCOL.pdf
uploaded 15/05/2020

Editorial Notes

12/01/2021: Publication reference added.
15/05/2020: Uploaded protocol (not peer reviewed) as an additional file.
06/04/2020: Trial’s existence confirmed by Pusan National University Yangsan Hospital Institutional Review Board.